Open AccessOptimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia
Author(s) -
Anouk E. Muller,
Nieko Punt,
Johan W. Mouton
Publication year - 2012
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dks468
Subject(s) - ceftazidime , pneumonia , medicine , ceftazidime/avibactam , clinical trial , antibacterial agent , intensive care medicine , bacterial pneumonia , antibiotics , outcome (game theory) , randomized controlled trial , microbiology and biotechnology , pseudomonas aeruginosa , bacteria , biology , genetics , mathematics , mathematical economics
The %fT>MIC of ceftazidime has been shown to correlate with microbiological outcome of Gram-negative bacteria (GNB) in preclinical studies. However, clinical data are still lacking. We explored the relationship of ceftazidime exposure and outcome in patients with nosocomial pneumonia using data from a recent randomized, double-blind Phase 3 clinical trial.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom